The most award winning

healthcare information source.


IRB Advisor

View Archived Issues


IRB Advisor 2015-02-01


Standard of Care Draft Guidance Praised, Criticized

Weighing in on a recent standard of care guidance published by the Office for Human Research Protections.

Read More

SUPPORT study that started controversy was complicated

A study called SUPPORT, short for Surfactant, Positive Pressure, and Oxygenation Randomized Trial, was a major reason behind recent draft guidance published by the Office for Human Research Protections (OHRP).

Read More

NIH issues guidance promoting central IRB use

The National Institutes of Health (NIH) is officially promoting the use of a single IRB for large, multisite clinical trials.

Read More

New SACHRP member brings legal and bioethical perspective to board

IRB Advisor asked Holly Fernandez Lynch, JD, MBioethics, executive director of the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School, Cambridge, MA, to discuss her role in joining the Secretary’s Advisory Committee on Human Research Protections (SACHRP). Before joining the Petrie-Flom Center, Lynch was a senior policy and research analyst for the Presidential Commission for the Study of Bioethical Issues’ report on the Guatemala STD inoculation study.

Read More

When creating a resource guide, hyperlinks can be useful

The main goal of creating an IRB resource guide is for it to be used and useful. If it’s too large and difficult to search, such as a 50-page paper document, or if it’s too cumbersome, such as a spreadsheet, staff might avoid it.

Read More

Guest column: Is “Right to Try” the right fit for better access to investigational drugs?

There is a constant struggle between giving people, particularly the terminally ill, access to new treatments quickly, while also ensuring that those treatments are as safe and effective as possible. The debate continues with the proposal and passage of state “Right to Try” laws, which would give terminally ill people access to investigational drugs that have completed Phase I studies.

Read More